SG11202006494VA - Therapeutic peptides and methods for treating autoimmune related disease - Google Patents
Therapeutic peptides and methods for treating autoimmune related diseaseInfo
- Publication number
- SG11202006494VA SG11202006494VA SG11202006494VA SG11202006494VA SG11202006494VA SG 11202006494V A SG11202006494V A SG 11202006494VA SG 11202006494V A SG11202006494V A SG 11202006494VA SG 11202006494V A SG11202006494V A SG 11202006494VA SG 11202006494V A SG11202006494V A SG 11202006494VA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- related disease
- treating autoimmune
- therapeutic peptides
- autoimmune related
- Prior art date
Links
- 230000001363 autoimmune Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862614262P | 2018-01-05 | 2018-01-05 | |
| US16/184,129 US20190194290A1 (en) | 2010-10-19 | 2018-11-08 | Methods for preventing, modulating and/or reducing cardiovascular disease |
| PCT/US2019/012425 WO2019136307A1 (en) | 2018-01-05 | 2019-01-04 | Therapeutic peptides and methods for treating autoimmune related disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006494VA true SG11202006494VA (en) | 2020-08-28 |
Family
ID=67144298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006494VA SG11202006494VA (en) | 2018-01-05 | 2019-01-04 | Therapeutic peptides and methods for treating autoimmune related disease |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3735260B1 (https=) |
| JP (2) | JP7511242B2 (https=) |
| CN (2) | CN119157997A (https=) |
| AU (1) | AU2019205328B2 (https=) |
| BR (1) | BR112020013716A2 (https=) |
| CA (1) | CA3086193A1 (https=) |
| MX (1) | MX2020007081A (https=) |
| SG (1) | SG11202006494VA (https=) |
| WO (1) | WO2019136307A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190263888A1 (en) | 2010-10-19 | 2019-08-29 | Op-T Llc | Therapeutic peptides and methods for treating autoimmune related disease |
| ES2957957T3 (es) | 2010-10-19 | 2024-01-30 | Op T Llc | Péptidos para modular la actividad de linfocitos T y usos de los mismos |
| US11793854B2 (en) | 2019-03-21 | 2023-10-24 | Op-T Llc | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction |
| JP2022540731A (ja) * | 2019-07-12 | 2022-09-16 | オーピー－ティー エルエルシー | ペプチドおよび疾患の治療方法 |
| EP4135742A2 (en) * | 2020-04-17 | 2023-02-22 | Op-T Llc | Bioactive peptides and methods of use thereof |
| WO2021231898A2 (en) * | 2020-05-14 | 2021-11-18 | Op-T Llc | Nanoparticle compositions and uses thereof |
| WO2022036495A1 (en) * | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| CN115807071B (zh) * | 2022-09-02 | 2025-09-26 | 宁夏医科大学 | 检测试剂在制备2型糖尿病伴动脉粥样硬化诊断工具中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7495090B2 (en) * | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
| WO2005006949A2 (en) * | 2003-07-07 | 2005-01-27 | Wagner David H | Methods for predicting development of auto-immune diseases and treatment of same |
| US7449200B2 (en) * | 2006-04-17 | 2008-11-11 | Gp Medical, Inc. | Nanoparticles for protein/peptide delivery and delivery means |
| ES2957957T3 (es) * | 2010-10-19 | 2024-01-30 | Op T Llc | Péptidos para modular la actividad de linfocitos T y usos de los mismos |
| JP6285923B2 (ja) * | 2012-06-22 | 2018-02-28 | トラスティーズ・オブ・ダートマス・カレッジ | 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用 |
| EP3123176A4 (en) * | 2014-03-23 | 2018-04-25 | The Regents of the University of Colorado | Diagnosis of multiple sclerosis in human and animal subjects |
-
2019
- 2019-01-04 BR BR112020013716-2A patent/BR112020013716A2/pt unknown
- 2019-01-04 AU AU2019205328A patent/AU2019205328B2/en active Active
- 2019-01-04 JP JP2020557124A patent/JP7511242B2/ja active Active
- 2019-01-04 WO PCT/US2019/012425 patent/WO2019136307A1/en not_active Ceased
- 2019-01-04 CN CN202411324616.4A patent/CN119157997A/zh active Pending
- 2019-01-04 SG SG11202006494VA patent/SG11202006494VA/en unknown
- 2019-01-04 CN CN201980017176.9A patent/CN111801110B/zh active Active
- 2019-01-04 EP EP19736089.4A patent/EP3735260B1/en active Active
- 2019-01-04 CA CA3086193A patent/CA3086193A1/en active Pending
- 2019-01-04 MX MX2020007081A patent/MX2020007081A/es unknown
-
2024
- 2024-06-17 JP JP2024097199A patent/JP2024123100A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020007081A (es) | 2020-10-28 |
| CN119157997A (zh) | 2024-12-20 |
| CN111801110B (zh) | 2024-10-18 |
| EP3735260B1 (en) | 2026-03-04 |
| WO2019136307A1 (en) | 2019-07-11 |
| AU2019205328B2 (en) | 2025-04-03 |
| EP3735260A1 (en) | 2020-11-11 |
| JP2021510174A (ja) | 2021-04-15 |
| CN111801110A (zh) | 2020-10-20 |
| CA3086193A1 (en) | 2019-07-11 |
| JP7511242B2 (ja) | 2024-07-05 |
| BR112020013716A2 (pt) | 2020-12-22 |
| EP3735260A4 (en) | 2021-12-08 |
| JP2024123100A (ja) | 2024-09-10 |
| AU2019205328A1 (en) | 2020-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202006494VA (en) | Therapeutic peptides and methods for treating autoimmune related disease | |
| IL276464A (en) | Methods and preparations for administering therapeutic protein | |
| SG11202104461XA (en) | Therapeutic methods | |
| IL281449A (en) | Anti-ifnar1 antibodies for the treatment of autoimmune diseases | |
| IL282871A (en) | Systems and methods for skin care | |
| IL281441A (en) | Anti-cxcl13 antibodies for the treatment of autoimmune diseases and cancer | |
| LT3773689T (lt) | Antigeniniai peptidai, skirti vėžio prevencijai ir gydymui | |
| ZA201905851B (en) | Peptides and methods for the treatment of diabetes | |
| SG11202104178TA (en) | Peptides and pharmaceutical compositions for treating eye diseases | |
| ZA201905372B (en) | Therapeutic and neuroprotective peptides | |
| PT3600415T (pt) | Anticorpo contra recetor de activina do recetor do tipo ii para utilização no tratamento de insuficiência cardíaca | |
| IL290520A (en) | Medicinal peptides | |
| IL275340A (en) | Peptides and other active compounds to treat pain and increase pain sensitivity | |
| IL285144A (en) | Medicinal peptides | |
| IL283443A (en) | Use of vdac inhibitors to treat autoimmune diseases | |
| GB201805207D0 (en) | Autoimmune therapy | |
| IL276639A (en) | Materials and methods for the treatment of dysproliferative diseases | |
| ZA201904386B (en) | S-arrestin peptides and therapeutic uses thereof | |
| IL284462A (en) | Tissue treatment systems and methods | |
| EP3628048A4 (en) | PEPTIDES FOR CANCER TREATMENT | |
| IL280564A (en) | Selection of therapeutic proteins under simulated conditions in the living body | |
| GB201810635D0 (en) | Peptides and cancer treatment | |
| HK40040300A (en) | Therapeutic peptides and methods for treating autoimmune related disease | |
| IL268844A (en) | Peptides and methods of treating dystrophy-related diseases by them | |
| GB201903547D0 (en) | Treatment for autoimmune diseases |